Our Council and Expert Panels

ACE Council

The ACE Council was formed as an advisory body to steer the Agency’s development to drive appropriate healthcare in Singapore. Led by an eminent senior clinician, the Council comprises well-respected senior medical specialists and professionals across a range of disciplines.

The combined expertise and experience of Council members in medicine, research and academia, health economics, legal, social policy and government policy, present a holistic perspective to guide the Agency's development.

The Council's terms of reference:

  1. To advise the Ministry on the development of initiatives to promote the use of evidence-based, safe and cost-effective medicines in public hospitals and institutions (PHIs).
  2. To develop strategies to harmonise formulary drugs across PHIs where appropriate and to facilitate timely listing of subsidised drugs.
  3. To advocate appropriate use of medicines by:
    • promoting the use of generic alternatives (including biosimilars) of medicines, where available;
    • working collaboratively with stakeholders to influence appropriate use of medicines in the PHIs (including compliance with ACE Guidance, where available);
    • facilitating the sharing of national drug utilisation data to provide PHIs with appropriate benchmark for reviewing each PHI’s practices.

Professor Chee Yam Cheng (since May 2016)


  • Senior Advisor, National Healthcare Group
Dr Daphne Khoo (since May 2016)

(Ex Officio)

  • Executive Director, Agency for Care Effectiveness
Mr Augustin Lee (since May 2016)
  • Chief Executive Officer, CPF Board  
Professor Teo Eng Kiong (since Jun 2020)
  • Master, Academy of Medicine, Singapore
  • Chief Executive Officer, Sengkang General Hospital
  • Deputy Group Chairman Medical Board (Regional Hospital Network), Singapore Health Services Pte Ltd
  • Senior Consultant, Gastroenterology & Hepatology, Department of General Medicine, Sengkang General Hospital
Associate Professor Toh Han Chong (since
Aug 2019)
  • Deputy Medical Director (Strategic Partnerships) and Senior Consultant, National Cancer Centre Singapore
Assistant Professor Jean Liu (since Aug 2019)
  • Assistant Professor, Division of Social Sciences (Psychology), Yale-NUS College
Associate Professor Lita Chew (since Aug 2019)
  • Head of Pharmacy Department, National Cancer Centre Singapore 
Ms Margaret Lee (since Aug 2019)
  • Chief Nurse, Alexandra Hospital
Ms Olivia Khoo (since Aug 2019)
  • Head of Department of Medical Social Services, Singapore General Hospital 
Ms Tan-Huang Shuo Mei (since Aug 2019)
  • Senior Director, Special Projects, SingHealth
Associate Professor Suresh Sahadevan (since Aug 2019)
  • Senior Consultant, Departments of General Medicine and Geriatric Medicine, Tan Tock Seng Hospital 
Ms K Thanaletchimi (since Aug 2019)
  • Vice President, NTUC Central Committee
  • President, Healthcare Services Employees’ Union (HSEU)
Dr Wong Tien Hua (since May 2016)
  • Director, Mutual Healthcare Pte Ltd, Singapore
  • Past President - Singapore Medical Association
Adjunct Associate Professor Tan Tze Lee (since Aug 2019)
  • President, College of Family Physicians Singapore
  • Senior Partner, The Edinburgh Clinic
  • Adjunct Associate Professor in Family Medicine, Yong Loo Lin School of Medicine, National University of Singapore
Ms Tan Yee Peng (since May 2016)
  • Chartered Accountant


International Advisory Panel

The International Advisory Panel (IAP) plays a critical advisory role as ACE (i) conducts health technology assessment (HTA) on treatments and technologies, and (ii) strengthens its guidance development methodology and builds its evidence implementation efforts to support clinicians in practising evidence-based medicine, to achieve cost-effective and appropriate healthcare in Singapore. The Panel will also offer a global perspective, which will help us keep abreast of relevant developments and initiatives internationally. IAP members are appointed for a 2-year term starting from 1 Mar 2021 to 28 Feb 2023.

The IAP's terms of reference are to advise ACE on the following areas:

  1. Critique, recommend improvements and advise on ACE’s workplan and initiatives (e.g. drug and medical technology evaluation methods and processes, manufacturer submission’s methods and process manual, guidance development methods and processes) to keep abreast with international best practices;
  2. Provide insights on emerging trends and developments in HTA, and/or guidance development and evidence implementation;
  3. Share approaches to guide Singapore’s implementation efforts to build capabilities in HTA, guidance development and execution of evidence-based practice; and conduct training for ACE staff in these areas; and
  4. Connect ACE to international networks in the area of HTA, guidance development and/or evidence implementation.

Current IAP Members

Meindert Boysen (since Mar 2019)
  • Deputy Chief Executive and Director, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), United Kingdom
  • Board of Directors, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) from 2017 to 2020

Prof Terry Campbell (since Mar 2021)
  • Emeritus Professor of Medicine, University of New South Wales (UNSW Sydney), Australia
  • Chair, Prostheses List Advisory Committee (PLAC), Commonwealth of Australia
  • Director of Research, St Vincent’s Hospital
Sarah Fitt (since Mar 2021)
  • Chief Executive, Pharmaceutical Management Agency (PHARMAC), New Zealand
Prof Mark Jit (since Aug 2019)
  • Professor of Vaccine Epidemiology, Department of Infectious Disease Epidemiology, Faculty of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, United Kingdom
  • Visiting Professor, School of Public Health, University of Hong Kong
Prof Nicholas Latimer (since Mar 2021)
  • Professor of Health Economics, School of Health & Related Research, The University of Sheffield, United Kingdom
  • Member, National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee B
  • Member, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Health Science Policy Council
Suzanne McGurn (since Mar 2021)
  • President and Chief Executive Officer, Canadian Agency for Drugs & Technologies in Health (CADTH), Canada
  • Member, Health Technology Assessment International (HTAi) Nominating Committee
Prof Tracy Merlin (since Mar 2019)
  • Professor of Health Technology Assessment, School of Public Health, University of Adelaide, Australia
  • Director, Adelaide Health Technology Assessment (AHTA)
  • Chair, Board of the International Network of Agencies for Health Technology Assessment (INAHTA)
  • Chair, English Editorial Board, International HTA Glossary

Prof Debra Rowett (since Apr 2020)
  • Discipline Leader Pharmacy: External Relations, UniSA Clinical and Health Sciences, University of South Australia
  • Director, Drug and Therapeutics Information Service (DATIS), Southern Adelaide Local Health Network
  • President, Council of Pharmacy Schools: Australia and New Zealand
  • Member, National Drug Utilisation Sub-Committee of Pharmaceutical Benefits Advisory Committee (PBAC)
  • Former President, Australian Pharmacy Council
Prof Tim Shaw (since Apr 2020)
  • Professor of eHealth and Director of Research in Implementation Science and eHealth (RISe), Faculty of Medicine and Health, The University of Sydney, Australia
  • Director of Research, Digital Health Cooperative Research Centre
Prof Per Olav Vandvik (since Apr 2020)
  • Chief Executive Officer, MAGIC Evidence Ecosystem Foundation, Norway
  • Professor of Medicine, Department of Health Management and Health Economics, University of Oslo
  • Senior Researcher, Norwegian Institute of Public Health, Oslo
  • Consultant, Department of Medicine, Lovisenberg Diaconal Hospital, Oslo
Prof Allan Wailoo (since Mar 2019)
  • Professor of Health Economics, School of Health & Related Research, The University of Sheffield, United Kingdom
  • Director, National Institute for Health & Care Excellence (NICE) Decision Support Unit
  • Member, NICE Medical Technologies Appraisal Committee (MTAC)
  • Co-Director, National Institute for Health Research (NIHR) Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions

Prof Robyn Ward (since Mar 2017)
  • Executive Dean and Pro Vice-Chancellor, Faculty of Medicine and Health, The University of Sydney, Australia
  • Chair, Commonwealth Medical Services Advisory Committee (MSAC)
  • Member, Board of the Australian Red Cross Lifeblood
  • Member, Prosthesis List Advisory Committee (PLAC), Commonwealth of Australia
  • Member, Genomics Health Futures Mission Expert Advisory Committee, Commonwealth of Australia
  • Honorary Medical Officer (Oncology), Westmead Hospital, Sydney
  • Member, RAND Australia Advisory Board
Prof Andrew Wilson (since Mar 2019)
  • Director, Menzies Centre for Health Policy, School of Public Health, The University of Sydney, Australia
  • Chair, Pharmaceutical Benefits Advisory Committee (PBAC)
  • Chair, PICO Advisory Sub-Committee of the Commonwealth Medical Services Advisory Committee (MSAC)

Former IAP members

Prof Jonathan Craig 

Member from Mar 2017  - Feb 2021

  • Vice President & Executive Dean, College of Medicine and Public Health, Flinders University, Australia 
Prof Ron Goeree

Member from Mar 2017 - Feb 2019

  • Professor Emeritus, McMaster University, Canada
Prof Carole Longson

Member from Mar 2017 - Feb 2019

  • Former Director, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), United Kingdom
Dr Brian O’Rourke

Member from Mar 2019 - Feb 2021

  • Former President and Chief Executive Officer, Canadian Agency for Drugs & Technologies in Health (CADTH), Canada
Prof Paul Scuffham

Member from Mar 2017 - Feb 2019

  • Director, Centre for Applied Health Economics, Griffith University, Australia
Prof Mark Sculpher

Member from Mar 2017 - Feb 2019

  • Professor, Centre for Health Economics, University of York, United Kingdom
Prof Ken Stein

Member from Mar 2019 - Feb 2021

  • Professor of Public Health, College of Medicine and Health, University of Exeter, United Kingdom

ACE Consumer Panel 

The ACE Consumer Panel plays an important role in providing strategic advice to ACE and its technical committees on consumer engagement and education initiatives, and meaningfully including consumers' perspectives into ACE’s health technology assessments (HTA). The Panel comprises individuals from local patient organisations who represent a broad range of health conditions and have extensive lived experiences engaging with the Singapore healthcare system. Current Panel members have been appointed for a 2-year term from 1 Apr 2022 to 31 Mar 2024. 

The Panel’s terms of reference:

  1. Foster collaboration between ACE and patient organisations;
  2. Provide patient and/or societal perspectives to inform ACE’s initiatives to improve health literacy and encourage the appropriate use of health technologies;
  3. Provide guidance on appropriate methodologies to collect information on patients’ views and experiences to inform ACE's work;
  4. Review the format, content, and proposed communication strategies of ACE’s educational resources so that they meet the needs of patients, carers, and the public; and
  5. Provide guidance on opportunities to strengthen engagement with patients and the public across ACE’s different workstreams.
The members of the ACE Consumer Panel and their key appointments in their respective patient organisations are listed below.

Associate Professor Lau Tang Ching


  • Chairperson, The National Arthritis Foundation 
Dr Ritu Jain


  • President, Dystrophic Epidermolysis Bullosa Research Association (DEBRA) Singapore & DEBRA International
Dr Kalpana Bhaskaran
  • President, Diabetes Singapore
Dr Adrian Chan Kwok Wai
  • President, Asthma & Allergy Association Singapore
Ms Magdalene Chia
  • Lead, Caring Hearts Support Group, National University Heart Centre, Singapore
  • Patient Partner, NUHS Family & Patient Partners, NUHS Patient Advocacy & Support Office
Mr Ellil Mathiyan Lakshmanan
  • Co-Founder & President, Ostomy Association of Singapore
  • Mentor, SingHealth Patient Advocacy Network
Ms Geraldyn Lim
  • Chief Operating Officer & Director, Community Engagement, Singapore Cancer Society
Mr Tim Oei
  • Chief Executive Officer, The National Kidney Foundation
Dr Ong Kian Chung
  • Founder & President, Chronic Obstructive Pulmonary Disease Association (Singapore)
Ms Peng Hai Ying
  • Chief Executive Officer, Children’s Cancer Foundation
Ms Ai Ling Sim-Devadas
  • Mentor, SingHealth Patient Advocacy Network
  • Member, Global Patient and Family Advisory Board, The Beryl Institute
Ms Sherry Soon
  • Founder, Autoimmune Diseases SG
Mr Shameemullah Sulaiman
  • Member, Executive Committee of Crohn’s & Colitis Society of Singapore
Dr Shamala Thilarajah
  • President, Singapore National Stroke Association